Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Breast Cancer

Free Subscription 16.03.2026 1 AJR Am J Roentgenol 1 Am J Clin Pathol 1 Am J Surg 2 Ann Oncol 29 Ann Surg Oncol 5 Anticancer Res 3 BMC Cancer 4 Breast Cancer 1 Breast Cancer (Auckl) 2 Breast Cancer (Dove Med Press) 3 Breast Cancer Res 11 Breast Cancer Res Treat 5 Breast J 1 Cancer 3 Cancer Lett 2 Cancer Res 1 Carcinogenesis 7 Clin Breast Cancer 1 Clin Cancer Res 2 Eur J Cancer 8 Eur J Surg Oncol 5 Eur Radiol 1 Exp Cell Res 1 Gene 5 Histopathology 4 Int J Cancer 2 Int J Oncol 3 Int J Radiat Oncol Biol Phys 1 J Biol Chem 5 J Clin Oncol 1 J Surg Oncol 2 Lancet 4 Lancet Oncol 3 Mod Pathol 5 NPJ Breast Cancer 3 Oncogene 1 Oncol Rep 2 PLoS Comput Biol 1 PLoS Med 8 PLoS One 2 Proc Natl Acad Sci U S A 1 Radiol Imaging Cancer 1 Radiologia (Engl Ed) 1 Semin Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. OLUYEMI ET, Grimm LJ, Goldman L, Lee M, et al
   False-Negative Screening and Diagnostic Mammograms in the National Mammography Database From 2010 to 2022.
   AJR Am J Roentgenol. 2025 Oct 22. doi: 10.2214/AJR.25.33636.
   PubMed         Abstract available
   
   

   
   Am J Clin Pathol

2. YILMAZ F, Hacking SM, Donegan L, Wang L, et al
   In Search of Calcifications : Histologic Analysis and Diagnostic Yield of Stereotactic Core Needle Breast Biopsies.
   Am J Clin Pathol. 2023;160:200-209.
   PubMed         Abstract available
   
   

   
   Am J Surg

3. DELOS SANTOS S, Invernizzi M, Liu C, Tong X, et al
   Utilizing post-imaging surveys to guide development of photoacoustic computed technology for breast imaging.
   Am J Surg. 2026;254:116828.
   PubMed         Abstract available
   
   

   
   Ann Oncol

4. SACKS R, Gandhi S
   Is more always better? Low-dose pembrolizumab as a practical step toward more equitable triple-negative breast cancer care.
   Ann Oncol. 2026 Mar 4:S0923-7534(26)00061-X. doi: 10.1016/j.annonc.2026.
   PubMed        
   
   
5. LOIBL S, Azim HA Jr, Bachelot T, Berveiller P, et al
   ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC).
   Ann Oncol. 2023;34:849-866.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

6. KUEMMEL S, Fasching PA, Schmid P, Harbeck N, et al
   ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.
   Ann Surg Oncol. 2026 Mar 12. doi: 10.1245/s10434-026-19310.
   PubMed        
   
   
7. AYUB S, Liu Y, Postlewait LM, Arciero C, et al
   ASO Author Reflections: Where You Live and How Much You Make Matters in Breast Cancer Care.
   Ann Surg Oncol. 2026 Mar 12. doi: 10.1245/s10434-026-19436.
   PubMed        
   
   
8. MASANAM MK, Kantor O
   Reply to: "Breast-Conserving Surgery After Neoadjuvant Therapy in Multiple Ipsilateral Breast Cancer: Points to Consider," by Sanli, Deniz et al.
   Ann Surg Oncol. 2026 Mar 11. doi: 10.1245/s10434-026-19358.
   PubMed        
   
   
9. TEKCAN SANLI DE, Sanli AN
   Breast-Conserving Surgery After Neoadjuvant Therapy in Multiple Ipsilateral Breast Cancer: Points to Consider.
   Ann Surg Oncol. 2026 Mar 11. doi: 10.1245/s10434-026-19357.
   PubMed        
   
   
10. RYU HH, Lee YJ, Yoo TK, Kim J, et al
    ASO Visual Abstract: Clinical Utility of Oncotype DX Testing in Synchronous Bilateral and Unilateral Multifocal Breast Cancer.
    Ann Surg Oncol. 2026 Mar 10. doi: 10.1245/s10434-026-19418.
    PubMed        
    
    
11. LEVINE A, Terrian L, Bishay D, Lawrence K, et al
    ASO Visual Abstract: Reassessing the Role of Regular Physical Examination in Post-treatment Breast Cancer Surveillance.
    Ann Surg Oncol. 2026 Mar 9. doi: 10.1245/s10434-026-19391.
    PubMed        
    
    
12. JIANG X, Huang Z, Wang X, Long J, et al
    ASO Visual Abstract: Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer-Development and Validation of a Clinical-Inflammatory Nomogram.
    Ann Surg Oncol. 2026 Mar 9. doi: 10.1245/s10434-026-19427.
    PubMed        
    
    
13. QU FL, Cheng JY, Li JJ, Shao ZM, et al
    ASO Author Reflections: Visions in Axilla Management with Clinical Advances in LymphPET for Breast Cancer.
    Ann Surg Oncol. 2026 Mar 7. doi: 10.1245/s10434-026-19472.
    PubMed        
    
    
14. AYUB S, Marra A, Liu Y, Postlewait LM, et al
    ASO Visual Abstract: Rurality and Income on Breast Cancer Outcomes: An Analysis of the SEER Database.
    Ann Surg Oncol. 2026 Mar 6. doi: 10.1245/s10434-026-19423.
    PubMed        
    
    
15. JUNG JJ, Kim HK, Kang E, Park EK, et al
    Enhancing Early Detection of Contralateral Breast Cancer in Breast Cancer Survivors Using AI-Assisted Mammography.
    Ann Surg Oncol. 2026 Mar 6. doi: 10.1245/s10434-026-19348.
    PubMed         Abstract available
    
    
16. YEE GN, Hwang S, Wilke LG, Freedman LM, et al
    ASO Visual Abstract: Commission on Cancer Quality Measure for Omission of Sentinel Lymph Node Biopsy (SNB) in Women Aged 70 Years or Older with Hormone Receptor-Positive (HR(+)) Invasive Breast Cancer (IBC) Undergoing Breast-Conserving Surgery (BCS):
    Ann Surg Oncol. 2026 Mar 3. doi: 10.1245/s10434-026-19390.
    PubMed        
    
    
17. KO G, Li Q, Liu N, Amir E, et al
    ASO Visual Abstract: Breast Cancer Surgery Wait Times and COVID-19-A Canadian Population-Based Analysis.
    Ann Surg Oncol. 2026 Mar 2. doi: 10.1245/s10434-026-19185.
    PubMed        
    
    
18. SCHRANK Z, Landrum K, Agala CB, Gallagher K, et al
    ASO Visual Abstract: Impact of Age on Use of Neoadjuvant Chemoimmunotherapy and Outcomes for Patients with Triple-Negative Breast Cancer.
    Ann Surg Oncol. 2026 Feb 28. doi: 10.1245/s10434-026-19334.
    PubMed        
    
    
19. CHEN C, Ru L
    ASO Visual Abstract: Prognostic Associations between Adjuvant Chemotherapy and Survival in T1b-T2N0M0 Medullary Breast Cancer: A Population-Based Study of 2343 Patients.
    Ann Surg Oncol. 2026 Feb 28. doi: 10.1245/s10434-026-19271.
    PubMed        
    
    
20. VETTER CD, Boughey JC, Johnson JE
    Cost-Effectiveness Analysis of Axillary Management Options at the Time of Contralateral Prophylactic Mastectomy.
    Ann Surg Oncol. 2026;33:3273-3282.
    PubMed         Abstract available
    
    
21. MORTON CR, Chen YJ, Williams K, Bloch RA, et al
    Efficiency of Sorting Site of Care for Frail Patients Undergoing Mastectomy.
    Ann Surg Oncol. 2026;33:3319-3326.
    PubMed         Abstract available
    
    
22. MRDUTT MM, Day CN, Madrigrano A, Boughey JC, et al
    ALND Experience During Breast Surgical Oncology Fellowship over the Years: An SSO/ASBrS Collaborative Analysis.
    Ann Surg Oncol. 2026;33:3414-3420.
    PubMed         Abstract available
    
    
23. GAILLARD T, Beddok A, Baadj Y, Feron JG, et al
    Outcomes of Second Breast-Conserving Surgery Without Reirradiation for Breast Tumor Recurrence.
    Ann Surg Oncol. 2026;33:3364-3373.
    PubMed         Abstract available
    
    
24. SHAO Y, Wang X, Yang J, Huang Y, et al
    From Proteomics to Pathology: S100A8's Impact on Breast Phyllodes Tumors Grading.
    Ann Surg Oncol. 2026;33:3651-3665.
    PubMed         Abstract available
    
    
25. LEONARD L, Yi M, Wingate E, Singh P, et al
    Axillary Management after Neoadjuvant Endocrine Therapy (NET).
    Ann Surg Oncol. 2026;33:3327-3337.
    PubMed         Abstract available
    
    
26. NAKADAIRA U, Sakai T, Ogiya A, Inoue Y, et al
    Feasibility of Omitting Axillary Dissection after Repeat Sentinel Lymph Node Biopsy for Ipsilateral Breast Tumor Recurrence: A Single-Center Retrospective Study.
    Ann Surg Oncol. 2026;33:3338-3344.
    PubMed         Abstract available
    
    
27. DONICA WRF, Shartzer DS, Ramakrishnan VG, Kuhl E, et al
    External Validation of a Pragmatic Scoring System for Predicting Upgrade of Atypical Ductal Hyperplasia at the Time of Surgery.
    Ann Surg Oncol. 2026;33:3283-3292.
    PubMed         Abstract available
    
    
28. KIM J, Park C, Jeon BJ, Pyon JK, et al
    Complication Profiles of Immediate Implant-Based versus Deep Inferior Epigastric Perforator Flap Breast Reconstruction following Nipple/Skin-Sparing Mastectomy in Patients with Prior Breast-Conserving Surgery and Radiotherapy.
    Ann Surg Oncol. 2026;33:3056-3065.
    PubMed         Abstract available
    
    
29. TOUADI M, Ross S, Sucandy I
    Robotic Partial Central Hepatectomy for Juxtahilar Tumor: Technique of Middle Hepatic Vein Tangential Reconstruction.
    Ann Surg Oncol. 2026;33:2926-2927.
    PubMed         Abstract available
    
    
30. KAUR S, Gastman B, Broderick KP, Momoh AO, et al
    Antibiotics and Surgical Site Infection in Expander-Based Breast Reconstruction Trial (ASSERT).
    Ann Surg Oncol. 2026;33:3033-3044.
    PubMed         Abstract available
    
    
31. SETO A, Pass A, Babkowski R, Volpicelli ER, et al
    Routine Use of a Standardized Mastectomy Diagram by Surgeons Improves Accuracy and Timeliness of the Final Pathological Report.
    Ann Surg Oncol. 2023;30:7124-7130.
    PubMed         Abstract available
    
    
32. FRANCO I, Alshalalfa M, Hernandez A, Mahal BA, et al
    Genomic Characterization of Aggressive Breast Cancer in Younger Women.
    Ann Surg Oncol. 2023;30:7569-7578.
    PubMed         Abstract available
    
    
33. MEURS CJC, van Bekkum S, van Rosmalen J, Menke-Pluijmers MBE, et al
    Validation and Clinical Utility of a Prediction Model for the Risk of Upstaging to Invasive Breast Cancer After a Biopsy Diagnosis Ductal Carcinoma In Situ.
    Ann Surg Oncol. 2023;30:7069-7080.
    PubMed         Abstract available
    
    
34. ZAVERI S, Everidge S, FitzSullivan E, Hwang R, et al
    Extremely Low Incidence of Local-Regional Recurrences Observed Among T1-2 N1 (1 or 2 Positive SLNs) Breast Cancer Patients Receiving Upfront Mastectomy Without Completion Axillary Node Dissection.
    Ann Surg Oncol. 2023;30:7015-7025.
    PubMed         Abstract available
    
    

    
    Anticancer Res

35. SALMINEN S, Tuomikoski L, Tarkkanen M, Wiklund T, et al
    Evaluation of Radiotherapy Dose in Secondary Breast Angiosarcoma: Implications for Pathogenesis.
    Anticancer Res. 2026;46:1517-1522.
    PubMed         Abstract available
    
    
36. WONG A, Narvaez-Rojas AR, Diehl W, Addis D, et al
    Tolerance and Outcomes of Partial Breast Radiation in a Community-based Setting.
    Anticancer Res. 2026;46:1523-1528.
    PubMed         Abstract available
    
    
37. JUNKINS K, Rodgers M, Phelan SA
    Oleuropein Induces Cytotoxicity and Peroxiredoxin Over-expression in MCF-7 Human Breast Cancer Cells.
    Anticancer Res. 2023;43:4333-4339.
    PubMed         Abstract available
    
    
38. CIPOLLA C, Vieni S, D'Agati E, Grassi N, et al
    Outcomes of Sentinel Lymph Node Biopsy for Patients With Node-positive Breast Cancer Treated With Neoadjuvant Chemotherapy.
    Anticancer Res. 2023;43:4643-4649.
    PubMed         Abstract available
    
    
39. CHOI YE, Sung K, Dong KS, Shin HB, et al
    The Effect of Respiratory Motion in Breast Intensity-modulated Radiation Therapy: 3D-Printed Dynamic Phantom Study.
    Anticancer Res. 2023;43:4425-4433.
    PubMed         Abstract available
    
    

    
    BMC Cancer

40. GUCLU T, Tanriverdi O, Bayrakci I, Demir B, et al
    Integration of Ki67 and Pan-Immune-Inflammation Value (PIV) into a predictive nomogram for pathologic complete response in triple-negative breast cancer : (Ki67 and inflammation in triple-negative breast cancer).
    BMC Cancer. 2026 Mar 11. doi: 10.1186/s12885-026-15842.
    PubMed        
    
    
41. HAO Y, Jiang X, Xiao J, Fan M, et al
    Genetic evidence for potential molecular mediators underlying the causal relationship between obesity and breast cancer: a two-step, two-sample Mendelian randomization study.
    BMC Cancer. 2026 Mar 10. doi: 10.1186/s12885-026-15744.
    PubMed         Abstract available
    
    
42. LIU CY, Lin YH, Tsai YF, Lu PY, et al
    Circulating tumor cells (CTCs) enumeration and machine-learning based diagnostic biomarkers for breast cancer detection.
    BMC Cancer. 2026 Mar 3. doi: 10.1186/s12885-026-15741.
    PubMed         Abstract available
    
    

    
    Breast Cancer

43. HIEDA H, Umemoto Y, Aasaumi A, Hashimoto N, et al
    Impact of sentinel lymph node biopsy versus axillary lymph node dissection on shoulder range of motion in early rehabilitation after breast cancer surgery.
    Breast Cancer. 2026 Mar 11. doi: 10.1007/s12282-026-01827.
    PubMed        
    
    
44. GIL-TORRALVO A, Dominguez-Cejudo MA, Molina-Pinelo S, Garrigos C, et al
    UGT2B17 as a predictive biomarker of complete pathological response in HER2 + breast cancer.
    Breast Cancer. 2026 Mar 6. doi: 10.1007/s12282-026-01840.
    PubMed        
    
    
45. KINOSHITA R, Hosoda M, Kato F, Kimura H, et al
    Three cases of whole breast irradiation for breast cancer in patients with Lymphangioleiomyomatosis (LAM).
    Breast Cancer. 2026 Mar 3. doi: 10.1007/s12282-026-01839.
    PubMed        
    
    
46. HASHIGUCHI H, Kouno N, Komatsu M, Shiino S, et al
    Validation of the postoperative prognostication tool PREDICT version 2.2 and 3.0 using data from the National cancer center hospital in Japan.
    Breast Cancer. 2026;33:415-425.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Auckl)

47. YATAWARA L, Hewavithana B, Ramanayake AP, Wickramasinghe S, et al
    Identification of Genetic Variants Among Breast Cancer Patients and At-Risk Individuals: A Cohort Study in Sri Lanka.
    Breast Cancer (Auckl). 2026;20:11782234261420605.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

48. ZHAI M, Bi J, Ke Z, Hu M, et al
    Efficacy and Safety of Neoadjuvant Stereotactic Body Radiotherapy (SBRT) Combined with Chemoimmunotherapy in Locally Advanced Breast Cancer: A Single-Center, Retrospective Pilot Study.
    Breast Cancer (Dove Med Press). 2026;18:577469.
    PubMed         Abstract available
    
    
49. ZHAO J, Luo X, Li H, Cheng Y, et al
    Combined Treatment with Shuyu Pills and Everolimus Suppresses Triple-Negative Breast Cancer Growth via the PI3K/AKT/mTOR Pathway.
    Breast Cancer (Dove Med Press). 2026;18:580570.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

50. ZHOU Q, Zhu Z, Zhao Y, Jing D, et al
    CD19(+)Ki67(+)B cells regulated by NAMPT as key modulators in triple-negative breast cancer with brain metastasis.
    Breast Cancer Res. 2026 Mar 9. doi: 10.1186/s13058-026-02251.
    PubMed         Abstract available
    
    
51. PHOENIX KN, Singh V, Murphy PA, Claffey KP, et al
    Transcriptomic profiles from normal and tumor tissue samples reveal distinct venule populations and novel tumor endothelial cell markers in breast cancer.
    Breast Cancer Res. 2026 Mar 3. doi: 10.1186/s13058-026-02249.
    PubMed        
    
    
52. LI Y, Wang W, Liang Y, Lai H, et al
    Advances in the study of pyrotinib for the treatment of HER2-positive breast cancer.
    Breast Cancer Res. 2026 Mar 3. doi: 10.1186/s13058-026-02255.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

53. BRUFSKY AM, Finn RS, Metzger O, Goncalves R, et al
    Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care.
    Breast Cancer Res Treat. 2026;216:22.
    PubMed         Abstract available
    
    
54. GAYFIELD S, Ma J, Waleski M, Kim J, et al
    Comparing infectious risk of Trastuzumab-deruxtecan to Trastuzumab-emtansine in patients with breast cancer.
    Breast Cancer Res Treat. 2026;216:23.
    PubMed         Abstract available
    
    
55. GIORDANO A, Graham N, Aizer AA, Tayob N, et al
    A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis.
    Breast Cancer Res Treat. 2026;216:24.
    PubMed         Abstract available
    
    
56. PESAPANE F, Nicosia L, Tantrige P, Schiaffino S, et al
    Inter-reader agreement of breast magnetic resonance imaging and contrast-enhanced mammography in breast cancer diagnosis: a multi-reader retrospective study.
    Breast Cancer Res Treat. 2023;202:451-459.
    PubMed         Abstract available
    
    
57. BUN A, Nagahashi M, Kuroiwa M, Komatsu M, et al
    Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin.
    Breast Cancer Res Treat. 2023;202:575-583.
    PubMed         Abstract available
    
    
58. SHARMA R
    Temporal patterns of breast cancer incidence, mortality, disability-adjusted life years and risk factors in 12 South American Countries, 1990-2019: an examination using estimates from the global burden of disease 2019 study.
    Breast Cancer Res Treat. 2023;202:529-540.
    PubMed         Abstract available
    
    
59. COSTEIRA B, da Silva FB, Fonseca F, Oom R, et al
    Long-term locoregional recurrence in patients treated for breast cancer.
    Breast Cancer Res Treat. 2023;202:551-561.
    PubMed         Abstract available
    
    
60. ZHANG X, Huang L, Sun J, Liu J, et al
    Monopolar spindle 1 contributes to tamoxifen resistance in breast cancer through phosphorylation of estrogen receptor alpha.
    Breast Cancer Res Treat. 2023;202:595-606.
    PubMed         Abstract available
    
    
61. SASADA S, Kondo N, Hashimoto H, Takahashi Y, et al
    Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer.
    Breast Cancer Res Treat. 2023;202:473-483.
    PubMed         Abstract available
    
    
62. HARTMANN S, Banys-Paluchowski M, Stickeler E, de Boniface J, et al
    Applicability of magnetic seeds for target lymph node biopsy after neoadjuvant chemotherapy in initially node-positive breast cancer patients: data from the AXSANA study.
    Breast Cancer Res Treat. 2023;202:497-504.
    PubMed         Abstract available
    
    
63. TAKADA M, Imoto S, Ishida T, Ito Y, et al
    A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer.
    Breast Cancer Res Treat. 2023;202:485-496.
    PubMed         Abstract available
    
    

    
    Breast J

64. XIAO X, Zhang W, Luo X, Peng Y, et al
    Exploring the Application of Contrast-Enhanced Ultrasound in ACR BI-RADS 4A Lesions (
    Breast J. 2026;2026:e6622181.
    PubMed         Abstract available
    
    
65. WANG L, Yuan Y, Jain U, Kleidi E, et al
    Recurrence Rate Following Breast Conservation Surgery: A Retrospective Cohort Study.
    Breast J. 2026;2026:e5063047.
    PubMed         Abstract available
    
    
66. CARELLI BC, Bagnoli F, Rocha EMC, Rinaldi JF, et al
    Evaluation of Shoulder Mobility After Breast Reconstruction With a Lipofilled Latissimus Dorsi Mini-Flap: A Prospective Cohort Study.
    Breast J. 2026;2026:5107548.
    PubMed         Abstract available
    
    
67. JANSSON SM, Austin CJ, Liu M, Craig SJ, et al
    Understanding Disparities in Breast Reconstruction Rates in Regional Populations Following Oncologic Resection of Breast Cancer: A 10-Year Retrospective Observational Cohort Study.
    Breast J. 2026;2026:1281318.
    PubMed         Abstract available
    
    
68. LOPES-JUNIOR LC, Minarini EJCDS, Pessanha RM, Neto LCBS, et al
    Symptom Clusters in Brazilian Women With Stage I and Stage III Nonmetastatic Breast Cancer: A Cross-Sectional Study.
    Breast J. 2026;2026:5427340.
    PubMed         Abstract available
    
    

    
    Cancer

69. BHIMANI J, O'Connell K, Blinder VS, Burganowski R, et al
    The landscape of chemotherapy modifications among women treated for stage I-IIIA breast cancer.
    Cancer. 2026;132:e70318.
    PubMed         Abstract available
    
    

    
    Cancer Lett

70. MOHOLKAR DN, Kandimalla R, Jeyabalan J, Singhal R, et al
    Exosomal Cannabidiol: A Promising Candidate for Targeted Oral Delivery against Breast Cancer.
    Cancer Lett. 2026 Mar 9:218416. doi: 10.1016/j.canlet.2026.218416.
    PubMed         Abstract available
    
    
71. DAI Y, Wu X, Cheng X, Shang J, et al
    tRF-1432 orchestrates RBMS1-IMPDH2 regulatory control to drive purine-dependent chemoresistance in breast cancer.
    Cancer Lett. 2026;646:218408.
    PubMed         Abstract available
    
    
72. YANG C, Liu J, Kang X, Wang Z, et al
    PANX1-mediated NLRP3 inflammasome activation promotes an adaptive doxorubicin resistance through IL-1beta signaling in breast cancer.
    Cancer Lett. 2026;645:218387.
    PubMed         Abstract available
    
    

    
    Cancer Res

73. AMAYA RAMIREZ CC, Loayza-Puch F
    Breast Cancer Metastatic Progression Requires mRNA Posttranscriptional Suppression.
    Cancer Res. 2023;83:2448-2449.
    PubMed         Abstract available
    
    
74. YU S, Wang Y, Gong X, Fan Z, et al
    LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity.
    Cancer Res. 2023;83:3220-3236.
    PubMed         Abstract available
    
    

    
    Carcinogenesis

75. 
    Retraction of: selective killing of human breast cancer cells by the styryl lactone (R)-goniothalamin is mediated by glutathione conjugation, induction of oxidative stress and marked reactivation of the R175H mutant p53 protein.
    Carcinogenesis. 2025;47:bgag009.
    PubMed        
    
    

    
    Clin Breast Cancer

76. HUANG H, Wei T, Zhang A, Zhang H, et al
    Comparison of Survival Outcomes in Young Patients With Breast Cancer Receiving Contralateral Prophylactic Mastectomy Versus Unilateral Mastectomy.
    Clin Breast Cancer. 2023;23:752-762.
    PubMed         Abstract available
    
    
77. FERNANDES I, Scorsato A, Kaliks R, Corpa M, et al
    Tumor-Infiltrating Lymphocytes in HER2-Low Breast Cancer.
    Clin Breast Cancer. 2023;23:e470-e479.
    PubMed         Abstract available
    
    
78. GARUTTI M, Cucciniello L, Arpino G, Fabi A, et al
    Risk-Based Therapeutic Strategies for HER2-Positive Early Breast Cancer: A Consensus Paper.
    Clin Breast Cancer. 2023;23:e458-e469.
    PubMed         Abstract available
    
    
79. D'ONOFRIO R, Omarini C, Toss A, Sperduti I, et al
    Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting.
    Clin Breast Cancer. 2023;23:712-720.
    PubMed         Abstract available
    
    
80. NAIR NS, Das A, Shet T, Kirti K, et al
    Accuracy of Intraoperative Frozen Section Analysis of Lymph Nodes in Women Undergoing Axillary Sampling for Treatment of Breast Cancer: Single Institution Audit.
    Clin Breast Cancer. 2023;23:e420-e423.
    PubMed         Abstract available
    
    
81. LIM ST, Choi HS, Kim K, Hahn S, et al
    Hounsfield Units Predict Survival of Patients With Estrogen Receptor-Positive and Human Epithelial Growth Factor Receptor 2-Negative Breast Cancer.
    Clin Breast Cancer. 2023;23:e424-e433.
    PubMed         Abstract available
    
    
82. PIVOT X, Spano JP, Espie M, Jouannaud C, et al
    Long Terms Follow-Up of the Randomized MetaspHER Study Comparing Intravenous Versus Subcutaneous Trastuzumab in Patients' With HER2-Positive Metastatic Breast Cancer.
    Clin Breast Cancer. 2023;23:e412-e419.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

83. PASCUAL J, Gil-Gil M, Proszek P, Zielinski C, et al
    Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients.
    Clin Cancer Res. 2023;29:4166-4177.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

84. NYBACK S, Poromaa IS, Lindman H, Hirschberg AL, et al
    Vaginal tamoxifen - A potential treatment option for vaginal atrophy symptoms in postmenopausal women who cannot use estrogen.
    Eur J Cancer. 2026;236:116261.
    PubMed         Abstract available
    
    
85. LIM JSJ, Ow SGW, Wong ALA, Lee MXW, et al
    Phase II study of trifluridine/tipiracil in metastatic breast cancers with or without prior exposure to fluoropyrimidines.
    Eur J Cancer. 2023;193:113311.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

86. SEKI H, Komiya T, Sowa Y, Kato M, et al
    Factors influencing surgical decision-making in breast cancer: A multicenter study in Japan.
    Eur J Surg Oncol. 2026;52:111739.
    PubMed         Abstract available
    
    
87. SENA G, Amaddeo A, Iannello A, Renne M, et al
    Efficacy and safety of electrochemotherapy in the treatment of cutaneous and sub-cutaneous recurrence from breast cancer: A single-center cohort study.
    Eur J Surg Oncol. 2026;52:111733.
    PubMed         Abstract available
    
    
88. SHEPHERDSON M, Edwards S, Bochner M
    Characteristics and management of women with a new breast cancer diagnosis after previous breast cancer in Australia and New Zealand.
    Eur J Surg Oncol. 2026;52:111732.
    PubMed         Abstract available
    
    
89. VAN DER VENNE WBW, Michiels R, van Kuijk SMJ, Tjan-Heijnen VCG, et al
    Establishing oncological safety of autologous fat transfer for total breast reconstruction: Results from the multicentre BREAST-I and BREAST-II trials.
    Eur J Surg Oncol. 2026;52:111417.
    PubMed         Abstract available
    
    
90. ERMANS SJE, Maas R, Hill TM, Usiskin SI, et al
    Comparison of contrast-enhanced mammography and breast MRI in tumour extent assessment: A systematic review and meta-analysis.
    Eur J Surg Oncol. 2026;52:111410.
    PubMed         Abstract available
    
    
91. TSUJIMOTO Y, Shiraishi M, Yamanaka H, Lee H, et al
    Virtual patient modeling for generative-AI-assisted treatment decision-making in lymphedema care: AI tends to favor more aggressive treatment.
    Eur J Surg Oncol. 2026;52:111391.
    PubMed         Abstract available
    
    
92. PARK WK, Oh N, Choi GS, Kim B, et al
    Development and external validation of an AI-guided navigation system for the safe dissection plane in robot-assisted nipple sparing mastectomy.
    Eur J Surg Oncol. 2026;52:111392.
    PubMed         Abstract available
    
    
93. VAN DAM P, Tomatis M, Ponti A, Marotti L, et al
    Locally advanced breast cancers: the EUSOMA experience.
    Eur J Surg Oncol. 2026;52:111303.
    PubMed         Abstract available
    
    

    
    Eur Radiol

94. GEERTSE TD, Tetteroo E, Smid-Geirnaerdt MJA, Duijm LEM, et al
    Applying the "positive predictive value-recall diagram" to monitor performance and provide recommendations for screening radiologists.
    Eur Radiol. 2026;36:1919-1931.
    PubMed         Abstract available
    
    
95. SCHIAFFINO S, Bernardi D, Healy N, Marino MA, et al
    ESR Essentials: artificial intelligence in breast imaging-practice recommendations by the European Society of Breast Imaging.
    Eur Radiol. 2026;36:1909-1918.
    PubMed         Abstract available
    
    
96. LIU Y, Wu J, Zhang W, Wang T, et al
    Preoperative contrast-enhanced ultrasound combined with intra-lymph node methylene blue injection for sentinel lymph node identification: a minimally invasive sentinel lymph node biopsy tracing approach.
    Eur Radiol. 2026;36:863-873.
    PubMed         Abstract available
    
    
97. KIM HJ, Kim HH, Eom HJ, Choi WJ, et al
    Combined use of two artificial intelligence-based algorithms for mammography triaging: a retrospective simulation study.
    Eur Radiol. 2026;36:808-820.
    PubMed         Abstract available
    
    
98. JANSE MHA, Janssen LM, Wolters-van der Ben EJM, Moman MR, et al
    Deep learning-based radiomics does not improve residual cancer burden prediction post-chemotherapy in LIMA breast MRI trial.
    Eur Radiol. 2026;36:850-862.
    PubMed         Abstract available
    
    

    
    Exp Cell Res

99. JING L, Zhou K, Wang Z, Li Y, et al
    YTHDF1 shapes "cold" tumor and inhibits CD8(+) T cells infiltration and function in breast cancer.
    Exp Cell Res. 2023;432:113778.
    PubMed         Abstract available
    
    

    
    Gene

100. HUANG X, Song W
     Reassessing butyrate's central role in the vitamin D-gut-breast cancer axis.
     Gene. 2026;990:150060.
     PubMed        
     
     

     
     Histopathology

101. 
     Correction to 'A simple digital image analysis system for automated Ki67 assessment in primary breast cancer'.
     Histopathology. 2026 Mar 11. doi: 10.1111/his.70123.
     PubMed        
     
     
102. SHEPHERD DJ, Craig C, Valencia-Guerrero AL, Chattu S, et al
     Prostein (p501s) is expressed in primary extramammary Paget disease.
     Histopathology. 2026;88:1094-1098.
     PubMed         Abstract available
     
     
103. MISRA S, Gudi M, Allison KH, Brogi E, et al
     Mucin-producing breast lesions: a practical approach to diagnosis.
     Histopathology. 2026;88:939-957.
     PubMed         Abstract available
     
     
104. ZUO K, Shui R, Xu X, Yu B, et al
     Apocrine encapsulated papillary carcinoma: a comprehensive clinicopathological analysis of 28 cases.
     Histopathology. 2026;88:1075-1083.
     PubMed         Abstract available
     
     
105. CSERNI G, Kalman E, Udvarhelyi N, Papp E, et al
     Evaluation of the routine use of E-cadherin immunohistochemistry in the typing of breast carcinomas: results of a randomized diagnostic study.
     Histopathology. 2023;83:810-821.
     PubMed         Abstract available
     
     

     
     Int J Cancer

106. LWIN MW, Schoffer O, Streissnig C, Wimberger P, et al
     A cost-effectiveness analysis of breast cancer treatment in certified versus non-certified hospitals in Germany.
     Int J Cancer. 2026 Mar 9. doi: 10.1002/ijc.70388.
     PubMed         Abstract available
     
     
107. MUHAMMAD SNH, Azlan M, Fauzi AN
     Reprogramming innate immunity to overcome endocrine resistance in estrogen receptor-positive breast cancer.
     Int J Cancer. 2026 Mar 7. doi: 10.1002/ijc.70421.
     PubMed         Abstract available
     
     
108. FASCHING PA, Brucker C, Decker T, Engel A, et al
     Real-world progression-free survival and overall survival in patients with HR(+)/HER2(-) advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study.
     Int J Cancer. 2026 Mar 6. doi: 10.1002/ijc.70397.
     PubMed         Abstract available
     
     
109. NORDENSKJOLD AE, Rios-Romero M, Dar H, Fornander T, et al
     Long-term benefit from adjuvant tamoxifen therapy for ER+ HER2- breast cancer by PR positivity.
     Int J Cancer. 2026 Mar 5. doi: 10.1002/ijc.70409.
     PubMed         Abstract available
     
     

     
     Int J Oncol

110. WANG W, Zhao P, Wang T, Wu W, et al
     Diverse roles of SERPINE1 in regulating cellular proliferation and invasion.
     Int J Oncol. 2026;68:58.
     PubMed         Abstract available
     
     
111. LI K, Wei L, Huang Y, Wu Y, et al
     [Corrigendum] Leptin promotes breast cancer cell migration and invasion via IL?18 expression and secretion.
     Int J Oncol. 2026;68:51.
     PubMed         Abstract available
     
     

     
     Int J Radiat Oncol Biol Phys

112. LEE S, Shu X, Derkach A, Reiner AS, et al
     Integrating genomic and non-genomic data to stratify the risk of contralateral breast cancer after radiotherapy.
     Int J Radiat Oncol Biol Phys. 2026 Feb 26:S0360-3016(26)00426.
     PubMed         Abstract available
     
     
113. GAO RW, Mullikin TC, Aziz KA, Afzal A, et al
     Postmastectomy Intensity Modulated Proton Therapy: 5-Year Oncologic and Patient-Reported Outcomes.
     Int J Radiat Oncol Biol Phys. 2023;117:846-856.
     PubMed         Abstract available
     
     
114. FORSTER T, Kohler C, Dorn M, Hafner MF, et al
     Noninferiority of Local Control and Comparable Toxicity of Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in Breast Cancer: 5-Year Results of the IMRT-MC2 Phase III Trial.
     Int J Radiat Oncol Biol Phys. 2023;117:857-868.
     PubMed         Abstract available
     
     

     
     J Biol Chem

115. ROSENTHAL KJ, Felix-Sanchez P, Forbush K, Rhoads N, et al
     AKAP2 is required for assembly of cytoskeletal signaling complexes that promote growth and metastasis of triple-negative breast cancer.
     J Biol Chem. 2026 Feb 26:111329. doi: 10.1016/j.jbc.2026.111329.
     PubMed         Abstract available
     
     

     
     J Clin Oncol

116. HUNTER NB, Parsons HA, Cope L, Canzoniero JV, et al
     The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.
     J Clin Oncol. 2026 Mar 10:JCO2502934. doi: 10.1200/JCO-25-02934.
     PubMed         Abstract available
     
     
117. HURVITZ SA, Layman RM, Curigliano G, Andre F, et al
     VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.
     J Clin Oncol. 2026 Mar 9:JCO2502643. doi: 10.1200/JCO-25-02643.
     PubMed         Abstract available
     
     
118. KIM J, Munster PN
     Cracks in the Estrogen Carcinogenesis of Breast Cancer.
     J Clin Oncol. 2026 Mar 5:JCO2503084. doi: 10.1200/JCO-25-03084.
     PubMed        
     
     
119. APOSTOL AI, Gronwald J, Cybulski C, Kim RH, et al
     Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2.
     J Clin Oncol. 2026 Feb 28:JCO2501648. doi: 10.1200/JCO-25-01648.
     PubMed         Abstract available
     
     
120. WILKINSON AN, Ellison LF, Billette JM, Seely JM, et al
     Impact of Breast Cancer Screening on 10-Year Net Survival in Canadian Women Age 40-49 Years.
     J Clin Oncol. 2023;41:4669-4677.
     PubMed         Abstract available
     
     

     
     J Surg Oncol

121. DE LA CRUZ KU G, Camarlinghi M, Mallouh MP, Torres-Roman JS, et al
     The impact of body mass index on oncoplastic breast surgery: A multicenter analysis.
     J Surg Oncol. 2023;128:1052-1063.
     PubMed         Abstract available
     
     

     
     Lancet

122. RIVERA S, Ghodssighassemabadi R, Auzac G, Brion T, et al
     5-year results of hypofractionated locoregional radiotherapy in early breast cancer HypoG-01 (UNICANCER): a French multicentre, randomised, non-inferiority, phase 3, open-label, controlled trial.
     Lancet. 2026;407:976-987.
     PubMed         Abstract available
     
     
123. COLES CE, Chatterjee S, Haviland JS
     Hypofractionated nodal radiotherapy in breast cancer: time for an updated standard of care?
     Lancet. 2026;407:920-921.
     PubMed        
     
     

     
     Lancet Oncol

124. LIU J, Liu Y, Song E, Li H, et al
     Fuzuloparib plus apatinib in BRCA-mutated breast cancer: balancing efficacy and accessibility in regional China - Authors' reply.
     Lancet Oncol. 2026;27:e126.
     PubMed        
     
     
125. QIU Z, Jin N
     Fuzuloparib plus apatinib in BRCA-mutated breast cancer: balancing efficacy and accessibility in regional China.
     Lancet Oncol. 2026;27:e125.
     PubMed        
     
     
126. 
     Global, regional, and national burden of breast cancer among females, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.
     Lancet Oncol. 2026;27:302-326.
     PubMed         Abstract available
     
     
127. PARK YH
     Beyond regional boundaries: crucial gaps in global breast cancer burden estimates.
     Lancet Oncol. 2026;27:270-271.
     PubMed        
     
     

     
     Mod Pathol

128. MAKHLOUF S, Althobiti M, Toss M, Muftah AA, et al
     The Clinical and Biological Significance of Estrogen Receptor-Low Positive Breast Cancer.
     Mod Pathol. 2023;36:100284.
     PubMed         Abstract available
     
     
129. BLACK MA, Neumann NM, Krings G, Najjar S, et al
     Genetic and Immunohistochemical Profiling of Mammary Hidradenoma and Comparison to Mucoepidermoid Carcinoma.
     Mod Pathol. 2023;36:100270.
     PubMed         Abstract available
     
     
130. ATALLAH NM, Wahab N, Toss MS, Makhlouf S, et al
     Deciphering the Morphology of Tumor-Stromal Features in Invasive Breast Cancer Using Artificial Intelligence.
     Mod Pathol. 2023;36:100254.
     PubMed         Abstract available
     
     

     
     NPJ Breast Cancer

131. SUN J, Ye J, Chen S, Yang Z, et al
     Artificial intelligence assisted multi-model pathological diagnosis of breast cancer based on multispectral autofluorescence images.
     NPJ Breast Cancer. 2026 Mar 12. doi: 10.1038/s41523-026-00915.
     PubMed         Abstract available
     
     
132. CAI X, Yang J, Wang W, Zhan X, et al
     The landscape of B and plasma cells in breast cancer: insights from single-cell and spatial transcriptomics.
     NPJ Breast Cancer. 2026 Mar 12. doi: 10.1038/s41523-026-00917.
     PubMed         Abstract available
     
     
133. LLOP-GUEVARA A, Pellegrino B, Pimentel I, Villacampa G, et al
     RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer.
     NPJ Breast Cancer. 2026 Mar 5. doi: 10.1038/s41523-026-00920.
     PubMed         Abstract available
     
     
134. JAIN D, Liao L, Talebian V, Hopkins M, et al
     Heterogeneity and immune microenvironment of early invasive estrogen receptor-positive breast cancer reveal an immune-rich subset.
     NPJ Breast Cancer. 2026 Mar 3. doi: 10.1038/s41523-025-00875.
     PubMed         Abstract available
     
     
135. GOUVEIA MC, Barroso-Sousa R, Lapuchesky L, Testa L, et al
     Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123.
     NPJ Breast Cancer. 2026 Mar 3. doi: 10.1038/s41523-026-00919.
     PubMed         Abstract available
     
     

     
     Oncogene

136. ZHAO W, Wang G, Wang P, Ma B, et al
     Arginine methylation-dependent stabilization of SUV39H1 promotes breast cancer growth.
     Oncogene. 2026 Mar 7. doi: 10.1038/s41388-026-03712.
     PubMed         Abstract available
     
     
137. CHO B, Furlan G, Lin P, Shen M, et al
     CHD1 is a synthetic lethal vulnerability in MYC-driven breast cancer.
     Oncogene. 2026 Mar 7. doi: 10.1038/s41388-026-03709.
     PubMed         Abstract available
     
     
138. WILLIAMS AE, Hoffmann EJ, Inman DR, Gari MK, et al
     Obesity and breast density enhance immune exclusion in the primary tumor microenvironment and promote breast cancer metastasis.
     Oncogene. 2026 Feb 28. doi: 10.1038/s41388-026-03718.
     PubMed         Abstract available
     
     

     
     Oncol Rep

139. AL SAYEGH H, Assi Z, Kanaan A, El Sibai M, et al
     CXCL1 in triple?negative breast cancer: Mechanisms, challenges, and therapeutic opportunities (Review).
     Oncol Rep. 2026;55:86.
     PubMed         Abstract available
     
     

     
     PLoS Comput Biol

140. VEITH T, Beck RJ, Brown JS, Andor N, et al
     Inverse game theory characterizes frequency-dependent selection driven by karyotypic diversity in triple negative breast cancer.
     PLoS Comput Biol. 2026;22:e1013897.
     PubMed         Abstract available
     
     
141. HUO X, Duan X, Huang X, Xue L, et al
     An integrative analysis reveals the mechanism of plastic stabilizers inducing breast cancer.
     PLoS Comput Biol. 2026;22:e1014025.
     PubMed         Abstract available
     
     

     
     PLoS Med

142. PAGE DB, Simanonok M, Hanes DA, Su A, et al
     Clinical potential and challenges of spatially profiling tumor-infiltrating lymphocytes in early-stage breast cancer.
     PLoS Med. 2026;23:e1004979.
     PubMed         Abstract available
     
     

     
     PLoS One

143. TU C, Zhong Y, Li H, Qi H, et al
     A cost-effective breast cancer screening strategy for Urban China: Findings from a Shenzhen-based modeling study.
     PLoS One. 2026;21:e0344253.
     PubMed         Abstract available
     
     
144. SUNG J, Song G, Jeong I, Ha J, et al
     Dosimetric benefits of 1.5 T MR-guided radiotherapy in partial breast treatment.
     PLoS One. 2026;21:e0342973.
     PubMed         Abstract available
     
     
145. SAKSORNCHAI K, Tawonwong T, Oonsiri P, Vimolnoch M, et al
     Dosimetric comparison study of ultrahypofractionated photon versus proton treatment plans in post breast-conserving surgery breast cancer.
     PLoS One. 2026;21:e0344699.
     PubMed         Abstract available
     
     
146. MYERS SP, Tsung C, Chen JC, Gokun Y, et al
     Factors correlated with financial hardship among cancer patients during the COVID-19 pandemic.
     PLoS One. 2026;21:e0342984.
     PubMed         Abstract available
     
     
147. ABUHIJLEH H, Zakria Z, Bawadi H, Hammad A, et al
     Unraveling the therapeutic potential of Elaeagnus angustifolia extract on triple-negative breast cancer (TNBC): An investigation using zebrafish model.
     PLoS One. 2026;21:e0344247.
     PubMed         Abstract available
     
     
148. KANG S, Yang S, Jia Y, Zhao S, et al
     Cost-effectiveness of sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer in China.
     PLoS One. 2026;21:e0343330.
     PubMed         Abstract available
     
     
149. JAVED S, Javed U, Mohamed Noor DA, Hanafiah NHM, et al
     Glycemic trajectories of fasting blood glucose on the pathological responses in breast cancer women with and without concomitant diabetes.
     PLoS One. 2026;21:e0319314.
     PubMed         Abstract available
     
     
150. LAFI Z, Alshaer W, Gharaibeh L, Alqudah DA, et al
     Synergistic combination of doxorubicin with hydralazine, and disulfiram against MCF-7 breast cancer cell line.
     PLoS One. 2023;18:e0291981.
     PubMed         Abstract available
     
     

     
     Proc Natl Acad Sci U S A

151. DING XH, Chen F, Yang F, Di GH, et al
     Phase separation of DDHD2 remodels lipid metabolism to dictate treatment sensitivity in luminal breast cancer.
     Proc Natl Acad Sci U S A. 2026;123:e2503019123.
     PubMed         Abstract available
     
     
152. CHEN HC, You SL, Lin CH, Sun CW, et al
     Elevated phthalate exposure and metabolic susceptibility increased breast cancer risk: A 20-y follow-up study in Taiwan.
     Proc Natl Acad Sci U S A. 2026;123:e2507008123.
     PubMed         Abstract available
     
     

     
     Radiol Imaging Cancer

153. REN Z, Fan X, Chumsaengsri S, Medved M, et al
     Automated Cluster-based Quantitative Analysis of Ultrafast DCE MRI for Differential Breast DCIS Grading.
     Radiol Imaging Cancer. 2026;8:e250432.
     PubMed         Abstract available
     
     

     
     Radiologia (Engl Ed)

154. SANCHEZ RUBIO N, Lannegrand Menendez B, Escudero Gonzalez L, Guerrero Martin M, et al
     The role of radiologists in the era of oncoplasty.
     Radiologia (Engl Ed). 2026;68:101632.
     PubMed         Abstract available
     
     

     
     Semin Oncol

155. FERRO A, Generali D, Caffo O, Caldara A, et al
     Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice?
     Semin Oncol. 2023;50.
     PubMed         Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum